Myotonic Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major myotonic dystrophy markets reached a value of US$ 96.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 260.4 Million by 2034, exhibiting a growth rate (CAGR) of 9.45% during 2024-2034.
The myotonic dystrophy market has been comprehensively analyzed in IMARC's new report titled "Myotonic Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myotonic dystrophy refers to a rare, inherited neuromuscular disorder characterized by muscle weakness and myotonia, a condition in which muscles have difficulty relaxing after contraction. This ailment results from an abnormal expansion of repetitive DNA sequences within specific genes, leading to dysfunctional RNA processing in affected tissues. The symptoms of the illness can vary widely and typically emerge gradually, with the severity often increasing over time. Some common manifestations include muscle stiffness, particularly in the hands and face, causing difficulty with activities, such as releasing handgrips or facial expressions. Weakness in other muscle groups, like the limbs and neck, can also be present, leading to reduced mobility. Additionally, individuals suffering from the disorder might experience heart rhythm abnormalities, cataracts, and cognitive impairment, further complicating the clinical picture. The diagnosis of myotonic dystrophy involves a combination of medical history evaluation, genetic testing, and electromyography (EMG) to measure muscle electrical activity.
The escalating incidences of genetic anomalies affecting the DMPK gene that trigger the abnormal expansion of repetitive DNA sequences, leading to impaired muscle function, are primarily driving the myotonic dystrophy market. In addition to this, the inflating utilization of physical and respiratory therapies on account of their various advantages, such as enhancing muscular function, optimizing respiratory capacity, and promoting overall mobility, is also creating a positive outlook for the market. Moreover, the widespread adoption of non-invasive procedures, including neuromuscular ultrasound, that aid in the visualization of muscle changes and contribute to early diagnosis, is further bolstering the market growth. Apart from this, the rising usage of antisense oligonucleotide therapy, which exhibits promising outcomes by targeting the underlying genetic aberrations responsible for the disorder, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of effective medications, such as anticonvulsants, mexiletine, and cardiac devices, to address the symptoms and reduce complications is also propelling the market growth. Furthermore, numerous technological advancements in the field of gene therapy, including CRISPR-Cas9, for rectifying genetic anomalies and correcting faulty genetic sequences, thereby opening new vistas for potential disease modification, are expected to drive the myotonic dystrophy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the myotonic dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myotonic dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myotonic dystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myotonic dystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myotonic dystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myotonic dystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the myotonic dystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myotonic dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myotonic dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of myotonic dystrophy across the seven major markets?
What is the number of prevalent cases (2018-2034) of myotonic dystrophy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of myotonic dystrophy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with myotonic dystrophy across the seven major markets?
What is the size of the myotonic dystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myotonic dystrophy?
What will be the growth rate of patients across the seven major markets?
Myotonic Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myotonic dystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myotonic dystrophy market?
What are the key regulatory events related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by status related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by phase related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by route of administration related to the myotonic dystrophy market?
The myotonic dystrophy market has been comprehensively analyzed in IMARC's new report titled "Myotonic Dystrophy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Myotonic dystrophy refers to a rare, inherited neuromuscular disorder characterized by muscle weakness and myotonia, a condition in which muscles have difficulty relaxing after contraction. This ailment results from an abnormal expansion of repetitive DNA sequences within specific genes, leading to dysfunctional RNA processing in affected tissues. The symptoms of the illness can vary widely and typically emerge gradually, with the severity often increasing over time. Some common manifestations include muscle stiffness, particularly in the hands and face, causing difficulty with activities, such as releasing handgrips or facial expressions. Weakness in other muscle groups, like the limbs and neck, can also be present, leading to reduced mobility. Additionally, individuals suffering from the disorder might experience heart rhythm abnormalities, cataracts, and cognitive impairment, further complicating the clinical picture. The diagnosis of myotonic dystrophy involves a combination of medical history evaluation, genetic testing, and electromyography (EMG) to measure muscle electrical activity.
The escalating incidences of genetic anomalies affecting the DMPK gene that trigger the abnormal expansion of repetitive DNA sequences, leading to impaired muscle function, are primarily driving the myotonic dystrophy market. In addition to this, the inflating utilization of physical and respiratory therapies on account of their various advantages, such as enhancing muscular function, optimizing respiratory capacity, and promoting overall mobility, is also creating a positive outlook for the market. Moreover, the widespread adoption of non-invasive procedures, including neuromuscular ultrasound, that aid in the visualization of muscle changes and contribute to early diagnosis, is further bolstering the market growth. Apart from this, the rising usage of antisense oligonucleotide therapy, which exhibits promising outcomes by targeting the underlying genetic aberrations responsible for the disorder, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of effective medications, such as anticonvulsants, mexiletine, and cardiac devices, to address the symptoms and reduce complications is also propelling the market growth. Furthermore, numerous technological advancements in the field of gene therapy, including CRISPR-Cas9, for rectifying genetic anomalies and correcting faulty genetic sequences, thereby opening new vistas for potential disease modification, are expected to drive the myotonic dystrophy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the myotonic dystrophy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for myotonic dystrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the myotonic dystrophy market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the myotonic dystrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the myotonic dystrophy market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current myotonic dystrophy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the myotonic dystrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the myotonic dystrophy market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the myotonic dystrophy market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of myotonic dystrophy across the seven major markets?
What is the number of prevalent cases (2018-2034) of myotonic dystrophy by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of myotonic dystrophy by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with myotonic dystrophy across the seven major markets?
What is the size of the myotonic dystrophy patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of myotonic dystrophy?
What will be the growth rate of patients across the seven major markets?
Myotonic Dystrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for myotonic dystrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the myotonic dystrophy market?
What are the key regulatory events related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by status related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by phase related to the myotonic dystrophy market?
What is the structure of clinical trial landscape by route of administration related to the myotonic dystrophy market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOTONIC DYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOTONIC DYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOTONIC DYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MYOTONIC DYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOTONIC DYSTROPHY - UNMET NEEDS
10 MYOTONIC DYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 MYOTONIC DYSTROPHY - MARKETED PRODUCTS
11.1 List of Myotonic Dystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MYOTONIC DYSTROPHY - PIPELINE DRUGS
12.1 List of Myotonic Dystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Tideglusib - AMO Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 IONIS-DMPKRX - Ionis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ERX 963 - Expansion Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DYNE-101 - Dyne Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Statusko
12.1.5 Pitolisant - Bioprojet
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MYOTONIC DYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOTONIC DYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOTONIC DYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myotonic Dystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myotonic Dystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myotonic Dystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myotonic Dystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myotonic Dystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myotonic Dystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myotonic Dystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myotonic Dystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myotonic Dystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myotonic Dystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myotonic Dystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myotonic Dystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myotonic Dystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myotonic Dystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myotonic Dystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myotonic Dystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myotonic Dystrophy - Access and Reimbursement Overview
16 MYOTONIC DYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOTONIC DYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOTONIC DYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MYOTONIC DYSTROPHY - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MYOTONIC DYSTROPHY - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MYOTONIC DYSTROPHY - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 MYOTONIC DYSTROPHY - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MYOTONIC DYSTROPHY - UNMET NEEDS
10 MYOTONIC DYSTROPHY - KEY ENDPOINTS OF TREATMENT
11 MYOTONIC DYSTROPHY - MARKETED PRODUCTS
11.1 List of Myotonic Dystrophy Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MYOTONIC DYSTROPHY - PIPELINE DRUGS
12.1 List of Myotonic Dystrophy Pipeline Drugs Across the Top 7 Markets
12.1.1 Tideglusib - AMO Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 IONIS-DMPKRX - Ionis Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ERX 963 - Expansion Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DYNE-101 - Dyne Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Statusko
12.1.5 Pitolisant - Bioprojet
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. MYOTONIC DYSTROPHY - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. MYOTONIC DYSTROPHY – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MYOTONIC DYSTROPHY - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Myotonic Dystrophy - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Myotonic Dystrophy - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Myotonic Dystrophy - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Myotonic Dystrophy - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Myotonic Dystrophy - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Myotonic Dystrophy - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Myotonic Dystrophy - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Myotonic Dystrophy - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Myotonic Dystrophy - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Myotonic Dystrophy - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Myotonic Dystrophy - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Myotonic Dystrophy - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Myotonic Dystrophy - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Myotonic Dystrophy - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Myotonic Dystrophy - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Myotonic Dystrophy - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Myotonic Dystrophy - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Myotonic Dystrophy - Access and Reimbursement Overview
16 MYOTONIC DYSTROPHY - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MYOTONIC DYSTROPHY MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MYOTONIC DYSTROPHY MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
